The Relationship between Metformin and Cancer in Patients with Type 2 Diabetes

• Main Authors: Hyun Hee Chung, Jun Sung Moon, Ji Sung Yoon, Hyoung Woo Lee, Kyu Chang Won
• Format: Article
• Language: English
• Published: Korean Diabetes Association 2013-04-01
• Series: Diabetes & Metabolism Journal
• Subjects: Diabetes mellitus, type 2; Metformin; Neoplasms
• Online Access: http://e-dmj.org/Synapse/Data/PDFData/2004DMJ/dmj-37-125.pdf
• ISSN: 2233-6079; 2233-6087

BackgroundRecently, several studies reported that the cancer incidence in type 2 diabetes patients is higher than in the general population. Although a number of risks are shared between cancer and diabetes patients, there have been few studies of its correlation. We evaluated the influences of several factors including low density lipoprotein cholesterol (LDL-C), albuminuria and use of metformin on the risk of cancer in patients with type 2 diabetes.MethodsWe enrolled 1,320 patients with at least 5 years of follow-up and 73 patients were diagnosed with cancer during this period. The associations of the risk factors with cancer incidence were evaluated by multiple regression analysis. The subjects were placed into two subgroups based on metformin dosage (<1,000 mg/day, ≥1,000 mg/day) and we compared cancer incidence using analysis of covariance.ResultsLDL-C and albuminuria were not significantly correlated with cancer risk. In contrast, metformin showed a reverse correlation with cancer risk (P=0.006; relative risk, 0.574). In the metformin nonadministration group, smoking, male gender, and high triglyceride levels tended to be contributing factors without statistical significance. Cancer occurence was lower in the low dose metformin group (less than 1,000 mg/day) (P=0.00).ConclusionThese results suggest that the administration of low dose metformin in patients with type 2 diabetes may be associated with a reduced risk of cancer.